[go: up one dir, main page]

CL2009000242A1 - Anillo monolitico intravaginal para tratar un defecto en la fase lutea, que comprende progesterona, un elastomero de polisiloxano y un aceite mineral, estando la progesterona dispersa homogeneamente en el elastomero de polisiloxano y procedimiento para fabricarlo. - Google Patents

Anillo monolitico intravaginal para tratar un defecto en la fase lutea, que comprende progesterona, un elastomero de polisiloxano y un aceite mineral, estando la progesterona dispersa homogeneamente en el elastomero de polisiloxano y procedimiento para fabricarlo.

Info

Publication number
CL2009000242A1
CL2009000242A1 CL2009000242A CL2009000242A CL2009000242A1 CL 2009000242 A1 CL2009000242 A1 CL 2009000242A1 CL 2009000242 A CL2009000242 A CL 2009000242A CL 2009000242 A CL2009000242 A CL 2009000242A CL 2009000242 A1 CL2009000242 A1 CL 2009000242A1
Authority
CL
Chile
Prior art keywords
progesterone
polysiloxane elastomer
defect
treating
manufacturing
Prior art date
Application number
CL2009000242A
Other languages
English (en)
Inventor
U Ahmed Salah
Tsao Jiaxiang
Mahashabde Anu
D Harrison Diane
Original Assignee
Ferring Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40939073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2009000242(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Bv filed Critical Ferring Bv
Publication of CL2009000242A1 publication Critical patent/CL2009000242A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/14—Contraceptive devices; Pessaries; Applicators therefor for use by females intra-uterine type
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F6/00—Contraceptive devices; Pessaries; Applicators therefor
    • A61F6/06—Contraceptive devices; Pessaries; Applicators therefor for use by females
    • A61F6/08—Pessaries, i.e. devices worn in the vagina to support the uterus, remedy a malposition or prevent conception, e.g. combined with devices protecting against contagion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/18—Feminine contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C45/00—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor
    • B29C45/0001—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor characterised by the choice of material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29C—SHAPING OR JOINING OF PLASTICS; SHAPING OF MATERIAL IN A PLASTIC STATE, NOT OTHERWISE PROVIDED FOR; AFTER-TREATMENT OF THE SHAPED PRODUCTS, e.g. REPAIRING
    • B29C45/00—Injection moulding, i.e. forcing the required volume of moulding material through a nozzle into a closed mould; Apparatus therefor
    • B29C45/17—Component parts, details or accessories; Auxiliary operations
    • B29C45/72—Heating or cooling
    • B29C45/7207—Heating or cooling of the moulded articles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2083/00—Use of polymers having silicon, with or without sulfur, nitrogen, oxygen, or carbon only, in the main chain, as moulding material
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29K—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES B29B, B29C OR B29D, RELATING TO MOULDING MATERIALS OR TO MATERIALS FOR MOULDS, REINFORCEMENTS, FILLERS OR PREFORMED PARTS, e.g. INSERTS
    • B29K2105/00—Condition, form or state of moulded material or of the material to be shaped
    • B29K2105/0005—Condition, form or state of moulded material or of the material to be shaped containing compounding ingredients
    • B29K2105/0035—Medical or pharmaceutical agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
    • B29L—INDEXING SCHEME ASSOCIATED WITH SUBCLASS B29C, RELATING TO PARTICULAR ARTICLES
    • B29L2031/00—Other particular articles
    • B29L2031/753—Medical equipment; Accessories therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Reproductive Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Mechanical Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Urology & Nephrology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Orthopedics, Nursing, And Contraception (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Surgical Instruments (AREA)
  • Compositions Of Macromolecular Compounds (AREA)

Abstract

Anillo monolítico intravaginal que comprende: a) progesterona, b) elastómero de polisiloxano entre 55-90% del peso total del anillo y c) hidrocarburo de uso farmacéutico o esteres de glicerol de un ácido graso, útil para el tratamiento de un defecto en la fase lutea; procedimiento de fabricación.
CL2009000242A 2008-02-04 2009-02-04 Anillo monolitico intravaginal para tratar un defecto en la fase lutea, que comprende progesterona, un elastomero de polisiloxano y un aceite mineral, estando la progesterona dispersa homogeneamente en el elastomero de polisiloxano y procedimiento para fabricarlo. CL2009000242A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2611508P 2008-02-04 2008-02-04
US13945408P 2008-12-19 2008-12-19

Publications (1)

Publication Number Publication Date
CL2009000242A1 true CL2009000242A1 (es) 2010-01-04

Family

ID=40939073

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2009000242A CL2009000242A1 (es) 2008-02-04 2009-02-04 Anillo monolitico intravaginal para tratar un defecto en la fase lutea, que comprende progesterona, un elastomero de polisiloxano y un aceite mineral, estando la progesterona dispersa homogeneamente en el elastomero de polisiloxano y procedimiento para fabricarlo.

Country Status (26)

Country Link
US (5) US8580293B2 (es)
EP (2) EP2249757B1 (es)
JP (2) JP5507467B2 (es)
KR (3) KR20140048321A (es)
CN (2) CN102098991B (es)
AR (1) AR070561A1 (es)
AU (1) AU2009210779B2 (es)
BR (1) BRPI0905946B8 (es)
CA (2) CA3016642A1 (es)
CL (1) CL2009000242A1 (es)
DK (2) DK2359807T3 (es)
EA (2) EA021615B1 (es)
ES (2) ES2645630T3 (es)
HR (1) HRP20171319T1 (es)
HU (1) HUE035634T2 (es)
IL (2) IL207376A (es)
LT (1) LT2249757T (es)
MX (2) MX337634B (es)
NZ (3) NZ611268A (es)
PL (2) PL2359807T3 (es)
PT (2) PT2359807T (es)
SG (2) SG187529A1 (es)
SI (2) SI2359807T1 (es)
TW (3) TWI599359B (es)
WO (1) WO2009099586A2 (es)
ZA (2) ZA201307321B (es)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140048321A (ko) 2008-02-04 2014-04-23 테바 위민즈 헬스 인코포레이티드 프로게스테론 함유 단일형 질내 링 및 그의 제조방법과 용도
AU2011270997A1 (en) * 2010-06-22 2013-01-10 Teva Women's Health, Inc. Intravaginal devices comprising anticholinergic agents, and methods of making thereof
US8580294B2 (en) 2010-10-19 2013-11-12 International Partnership For Microbicides Platinum-catalyzed intravaginal rings
EP2641602A1 (en) * 2012-03-23 2013-09-25 PregLem S.A. Method for treating gynecological diseases
ES2787882T3 (es) 2013-02-08 2020-10-19 Qpharma Ab Un dispositivo intravaginal, y un método para reducir la velocidad de difusión de ingredientes activos en dicho dispositivo intravaginal
CN103394127A (zh) * 2013-08-02 2013-11-20 苏州市马尔泰新材料有限公司 一种含有中西医药的阴道模具材料
CN103394128A (zh) * 2013-08-02 2013-11-20 苏州市马尔泰新材料有限公司 一种含有川芎的模具材料
CN103445892A (zh) * 2013-08-02 2013-12-18 苏州市马尔泰新材料有限公司 一种含有甲酯树脂和雌酚的阴道模具
CN103405810A (zh) * 2013-08-02 2013-11-27 苏州市马尔泰新材料有限公司 一种含有甲基丙烯酸甲酯树脂的阴道模具
CN103431930A (zh) * 2013-08-02 2013-12-11 苏州市马尔泰新材料有限公司 一种含有甲酯树脂的阴道模具
US10137031B2 (en) 2013-11-14 2018-11-27 International Partnership For Microbicides, Inc. Combination therapy intravaginal rings
HRP20241336T1 (hr) 2014-04-01 2024-12-20 Poly-Med, Inc. Kontraceptivni i srodni uređaj
WO2015198104A1 (es) * 2014-06-28 2015-12-30 Laboratorios Andromaco S.A. Pesario de cerclaje que contiene progesterona de liberación prolongada, sostenida y continua, útil para la prevención de parto prematuro
CN104546267B (zh) * 2015-01-13 2017-01-04 安徽农业大学 一种犬用宫外节育装置及其节育方法
BR112018012744A2 (pt) * 2015-12-21 2018-12-04 Bayer Oy método de fabricação de um anel vaginal
EP3542786A1 (en) * 2018-03-21 2019-09-25 ITF Research Pharma, S.L.U. Progesterone intravaginal devices
WO2020205805A1 (en) * 2019-03-29 2020-10-08 Martell Bridget Segmented eva intravaginal rings
US10918649B2 (en) 2019-06-21 2021-02-16 The Population Council, Inc. System for providing birth control
WO2021068239A1 (zh) 2019-10-12 2021-04-15 国家卫生健康委科学技术研究所 用于黄体支持的阴道缓释给药系统及其制备方法与应用
US20220186312A1 (en) * 2020-12-11 2022-06-16 Guzip Biomarkers Corporation Predictive method for assessing the success of embryo implantation

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL152819B (nl) 1949-04-07 Swift & Co Werkwijze voor het continu bereiden van mono-ammoniumdiwaterstoffosfaatdeeltjes en zo verkregen deeltjes.
US2863846A (en) 1950-05-04 1958-12-09 Dow Corning Organo silyl-silica filled siloxane elastomers and process for producing same
US2890188A (en) 1951-12-17 1959-06-09 Dow Corning Siloxane elastomers compounded with hydroxylated silanes
NL91756C (es) 1953-11-19
US3022951A (en) 1957-05-14 1962-02-27 Ibm Full adder
US3545439A (en) 1968-01-04 1970-12-08 Upjohn Co Medicated devices and methods
US3948262A (en) 1969-04-01 1976-04-06 Alza Corporation Novel drug delivery device
US3854480A (en) * 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
IL48277A (en) 1974-10-18 1978-03-10 Schering Ag Vaginal ring
DE3040978A1 (de) 1980-10-28 1982-05-27 Schering Ag, 1000 Berlin Und 4619 Bergkamen Vaginalring
US4629449A (en) 1982-07-29 1986-12-16 Alza Corporation Vaginal dispenser for dispensing beneficial hormone
US4816257A (en) 1985-09-20 1989-03-28 Research & Education Institute, Harbor-Ucla Medical Center Inc. Method for producing an in vivo environment suitable for human embryo transfer
US5188835A (en) 1986-06-16 1993-02-23 Kabi Pharmacia Ab Intravaginal devices
SE8602666D0 (sv) * 1986-06-16 1986-06-16 Leo Ab Intravaginal devices
FR2618329B1 (fr) 1987-07-22 1997-03-28 Dow Corning Sa Procede de fabrication d'un anneau capable d'assurer la liberation d'un agent therapeutique, et anneau fabrique par ce procede
US5084277A (en) 1988-08-30 1992-01-28 Greco John C Vaginal progesterone tablet
US5116619A (en) 1988-08-30 1992-05-26 Lee Roy Morgan Vaginal progesterone tablet
DE3838815A1 (de) * 1988-11-17 1990-05-23 Hoechst Ag Verfahren zum herstellen eines intravaginalen applikationssystems
US6264638B1 (en) 1989-12-07 2001-07-24 Ultrafem, Inc. Intravaginal drug delivery system and discharge collection device
US5340585A (en) * 1991-04-12 1994-08-23 University Of Southern California Method and formulations for use in treating benign gynecological disorders
US5393528A (en) 1992-05-07 1995-02-28 Staab; Robert J. Dissolvable device for contraception or delivery of medication
IT1256393B (it) 1992-11-17 1995-12-04 Inverni Della Beffa Spa Forme matriciali multistrato per il rilascio controllato di principi attivi
FI95768C (fi) * 1993-06-17 1996-03-25 Leiras Oy Emättimensisäinen antosysteemi
US5543150A (en) 1993-09-15 1996-08-06 Columbia Laboratories, Inc. Method of progesterone delivery and affect thereof
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6544546B1 (en) 1995-07-04 2003-04-08 Akzo Nobel, N.V. Ring-shaped devices
GB9522403D0 (en) 1995-11-01 1996-01-03 Hoechst Roussel Ltd Intravaginal drug delivery device
US5744463A (en) 1996-06-03 1998-04-28 Bair; Glenn O. Treatment of side effects of progestins and progesterone analogues used for birth control
US5869081A (en) * 1996-06-28 1999-02-09 The Population Council Progesterone vaginal ring for treatment of infertility
US5972372A (en) 1996-07-31 1999-10-26 The Population Council, Inc. Intravaginal rings with insertable drug-containing core
US6028064A (en) 1996-09-13 2000-02-22 New Life Pharmaceuticals Inc. Prevention of ovarian cancer by administration of progestin products
US5985861A (en) 1996-11-04 1999-11-16 Columbia Laboratories, Inc. Progesterone for treating or reducing ischemia
US5814329A (en) 1996-11-12 1998-09-29 Polytherapeutics, Inc. Hydrophilic polystyrene graft copolymer vehicle for intravaginal administration of pharmacologically active agents
US6416778B1 (en) 1997-01-24 2002-07-09 Femmepharma Pharmaceutical preparations and methods for their regional administration
US5993856A (en) 1997-01-24 1999-11-30 Femmepharma Pharmaceutical preparations and methods for their administration
US6056972A (en) 1997-02-26 2000-05-02 Dimera, Llc Method for reducing coronary artery reactivity
AU741482B2 (en) * 1997-05-07 2001-11-29 Allergan Pharmaceuticals International Limited Intravaginal drug delivery devices for the administration of testosterone and testosterone precursors
US6197327B1 (en) * 1997-06-11 2001-03-06 Umd, Inc. Device and method for treatment of dysmenorrhea
US6039968A (en) * 1997-06-24 2000-03-21 Hoechst Marion Roussel Intravaginal drug delivery device
US6245757B1 (en) 1997-10-03 2001-06-12 Research Corporation Technologies, Inc. Use of progestins to treat ischemic event
US6306914B1 (en) 1997-10-21 2001-10-23 Columbia Laboratories, Inc. Progestin therapy for maintaining amenorrhea
NZ330596A (en) 1998-06-05 2001-02-23 Dec Res Intravaginal devices allowing for increased uptake of active ingredients
ES2255266T3 (es) 1998-05-01 2006-06-16 Duramed Pharmaceuticals, Inc. Procedimiento de fabricacion por moldeo po inyeccion para dispositivos de liberacion controlada y dispositivo asi producido.
ATE246522T1 (de) 1998-06-19 2003-08-15 Oxibio Inc Implantierbare medizinische vorrichtung mit antiinfektiösen und kontrazeptiven eigenschaften
US7001609B1 (en) 1998-10-02 2006-02-21 Regents Of The University Of Minnesota Mucosal originated drug delivery systems and animal applications
US6056976A (en) 1998-11-12 2000-05-02 Leiras Oy Elastomer, its preparation and use
US6063395A (en) 1998-11-12 2000-05-16 Leiras Oy Drug delivery device especially for the delivery of progestins and estrogens
CN1210079C (zh) 2001-04-25 2005-07-13 上海市计划生育科学研究所 阴道环制剂及其应用
US20050197651A1 (en) 2001-04-25 2005-09-08 Chen Hai L. Vaginal ring preparation and its application
RU2302883C2 (ru) * 2001-08-31 2007-07-20 Шеринг Ой Система доставки лекарств
WO2003065924A1 (en) 2002-02-08 2003-08-14 Advanced Animal Technology Limited Control of a biological function
US9993424B2 (en) * 2002-03-27 2018-06-12 Allergan Pharmaceuticals International Limited Intravaginal matrix drug delivery devices
US20040151774A1 (en) 2002-10-31 2004-08-05 Pauletti Giovanni M. Therapeutic compositions for drug delivery to and through covering epithelia
US20040089308A1 (en) 2002-11-13 2004-05-13 Welch Robert A. Cervical ring to deliver medication
FR2849380A1 (fr) 2002-12-27 2004-07-02 Ernest Loumaye NOUVELLE UTILISATION D'UN AGONISTE DU GnRH
US7833545B2 (en) 2003-04-29 2010-11-16 The General Hospital Corporation Methods and devices for the sustained release of multiple drugs
US8404272B2 (en) 2003-06-26 2013-03-26 Poly-Med, Inc. Fiber-reinforced composite rings for intravaginal controlled drug delivery
ES2442675T3 (es) 2003-07-10 2014-02-12 Warner Chilcott (Ireland) Limited Dispositivos intravaginales de suministro de fármacos
US20050255157A1 (en) 2004-05-11 2005-11-17 Glenmark Pharmaceuticals Limited Sustained release, mucoadhesive vaginal pharmaceutical compositions
US7707169B2 (en) 2004-06-10 2010-04-27 Siemens Corporation Specification-based automation methods for medical content extraction, data aggregation and enrichment
AU2005265357B2 (en) 2004-07-09 2011-04-07 Laboratoire Hra Pharma Sustained release compositions containing progesterone receptor modulators
AR043476A1 (es) * 2004-09-09 2005-08-03 Dvoskin Victor Oscar Dispositivo de administracion regulada de sustancias para la insercion en una cavidad corporal y procedimiento para fabricar un medio de soporte de dichas sustancias
US7517914B2 (en) 2005-04-04 2009-04-14 Boston Scientificscimed, Inc. Controlled degradation materials for therapeutic agent delivery
US8399012B2 (en) 2006-04-17 2013-03-19 Kimberly-Clark Worldwide, Inc. Degradable therapeutic delivery device
CN101522174A (zh) 2006-05-10 2009-09-02 赢创德固赛有限责任公司 辊压热解制备的二氧化硅在药物组合物中的应用
US8828981B2 (en) 2007-02-06 2014-09-09 George Creasy Progesterone for the treatment or prevention of spontaneous preterm birth
US20080214512A1 (en) 2007-03-01 2008-09-04 Christian Seitz Pharmaceutical preparation containing a gestagen, and kit and method for treating endometriosis using the preparation
EP2136787B1 (en) 2007-03-22 2019-08-21 Berg LLC Topical formulations having enhanced bioavailability
EP2150271A1 (en) 2007-05-11 2010-02-10 The Texas A & M Univsersity System Hormone normalization therapy and uses thereof
KR20140048321A (ko) 2008-02-04 2014-04-23 테바 위민즈 헬스 인코포레이티드 프로게스테론 함유 단일형 질내 링 및 그의 제조방법과 용도

Also Published As

Publication number Publication date
SG187529A1 (en) 2013-02-28
IL207376A0 (en) 2010-12-30
JP6124411B2 (ja) 2017-05-10
TWI655947B (zh) 2019-04-11
BRPI0905946B8 (pt) 2021-05-25
SI2249757T1 (sl) 2017-10-30
US20230158044A1 (en) 2023-05-25
JP2011510984A (ja) 2011-04-07
IL221988A (en) 2015-03-31
JP2014167001A (ja) 2014-09-11
TWI549681B (zh) 2016-09-21
DK2359807T3 (en) 2017-10-16
US20140030311A1 (en) 2014-01-30
US10548904B2 (en) 2020-02-04
KR20100133969A (ko) 2010-12-22
BRPI0905946A2 (pt) 2015-06-30
WO2009099586A3 (en) 2010-01-14
EA201070919A1 (ru) 2011-04-29
NZ587758A (en) 2012-05-25
EP2359807A1 (en) 2011-08-24
MX337634B (es) 2016-03-14
CA2713943C (en) 2018-10-23
HRP20171319T1 (hr) 2017-10-20
EA021615B1 (ru) 2015-07-30
AU2009210779B2 (en) 2015-04-02
MX385981B (es) 2025-03-04
PL2249757T3 (pl) 2017-12-29
AR070561A1 (es) 2010-04-21
ZA201307321B (en) 2017-09-27
LT2249757T (lt) 2017-09-25
MX2010008545A (es) 2010-12-20
EP2359807B1 (en) 2017-07-26
PL2359807T3 (pl) 2017-12-29
SG10201605171QA (en) 2016-08-30
TW201526898A (zh) 2015-07-16
US20160279147A1 (en) 2016-09-29
EA031017B1 (ru) 2018-11-30
US20200405732A1 (en) 2020-12-31
EP2249757A2 (en) 2010-11-17
US20090202612A1 (en) 2009-08-13
ES2648640T3 (es) 2018-01-04
EP2249757A4 (en) 2011-07-20
CN104146948B (zh) 2018-01-02
ES2645630T3 (es) 2017-12-07
NZ611268A (en) 2015-03-27
KR20160055980A (ko) 2016-05-18
AU2009210779A1 (en) 2009-08-13
EA201491815A1 (ru) 2015-03-31
EP2249757B1 (en) 2017-08-09
HUE035634T2 (en) 2018-05-28
CN102098991A (zh) 2011-06-15
US11413294B2 (en) 2022-08-16
CN104146948A (zh) 2014-11-19
TWI599359B (zh) 2017-09-21
CN102098991B (zh) 2014-10-22
CA3016642A1 (en) 2009-08-13
BRPI0905946B1 (pt) 2020-09-29
KR20140048321A (ko) 2014-04-23
JP5507467B2 (ja) 2014-05-28
DK2249757T3 (en) 2017-10-16
ZA201307320B (en) 2017-03-29
WO2009099586A2 (en) 2009-08-13
PT2249757T (pt) 2017-11-15
SI2359807T1 (sl) 2017-10-30
PT2359807T (pt) 2017-11-07
IL207376A (en) 2012-09-24
TW200938204A (en) 2009-09-16
US10537584B2 (en) 2020-01-21
US8580293B2 (en) 2013-11-12
KR101730517B1 (ko) 2017-04-26
NZ596844A (en) 2014-03-28
CA2713943A1 (en) 2009-08-13
TW201630610A (zh) 2016-09-01

Similar Documents

Publication Publication Date Title
CL2009000242A1 (es) Anillo monolitico intravaginal para tratar un defecto en la fase lutea, que comprende progesterona, un elastomero de polisiloxano y un aceite mineral, estando la progesterona dispersa homogeneamente en el elastomero de polisiloxano y procedimiento para fabricarlo.
CL2011000214A1 (es) Composicion farmaceutica que comprende progesterona micronizada y aceite de cartamo tipo ii; y uso para el tratamiento de una condicion relacionada con la insuficiencia de secrecion de progesterona.
AR077199A1 (es) Composicion farmaceutica y procedimiento de tratamiento para la anticoncepcion de emergencia
CO6410314A2 (es) Proteínas de unión a il-17
MX2010009722A (es) Procedimiento de tratamiento del dolor cronico.
CL2012002606A1 (es) Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
AR106768A1 (es) Composiciones que comprenden cepas bacterianas
MX2018008908A (es) Tratamiento para modular la microbiota intestinal.
AR088083A1 (es) USO DE ANTICUERPOS DE UNION A IL-1b
CL2011000230A1 (es) Anticuerpo monoclonal humano aislado que se une al inhibidor de la via del factor tisular (tfpi); composicion farmaceutica que lo comprende; uso para tratar deficiencias adquiridas o geneticas de la coagulacion, o para acortar el tiempo de sangrado.
UY36452A (es) Novedosos compuestos moduladores de fxr (nr1h4)
CL2011001811A1 (es) Un metodo para tratar un paciente que ha sufrido un infarto agudo al miocardio que comprende el uso de un agente antifibrotico.
CL2012003281A1 (es) Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica.
CL2010000188A1 (es) Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso.
CL2013000063A1 (es) Un método para tratar a un sujeto que comprende administrar n-etil-n-fenil1,2-dihidroxi-4-hodroxi-5-cloro-1-metil-2-oxoquinolina-3-carboxamida opcionalmente deuterada, para el tratamiento de una enfermedad autoinmunitaria; una mezcla de los mismos; composición farmaceutica y su proceso de preparacion.
MX385872B (es) Uso de un anticuerpo que tiene la capacidad para ligarse a clnd 6 en el tratamiento o prevención de cáncer
ECSP10010446A (es) Uso de ranolazina para el tratamiento del dolor
CL2008002430A1 (es) Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc.
MX352328B (es) Formulaciones orales de ester de testosterona y metodos para el tratamiento de la deficiencia de testosterona que comprende estos.
MX2019000547A (es) Formulaciones de adamts13 liquidas y liofilizadas, estabilizadas.
CL2009000964A1 (es) Compuestos derivados de 1-aril-2-imino-1,2-dihidropiridina-3-carboxamida, antagonista del receptor adrenergico alfa 1d, composicion farmaceutica que los comprende; y su uso para el tratamiento o profilaxis de enfermedades del tracto urinario inferior.
AR087483A1 (es) Carbonato de calcio con tratamiento de superficie para la union y biorremediacion de composiciones que contienen hidrocarburos
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
MX2014000066A (es) Formulaciones mucoadhesivas en gel de alta dosificación de metronidazol de base acuosa y su uso para tratar la vaginosis bacteriana.
SV2017005466A (es) Pirazolpiridinaminas como inhibidores de mknk1 y mknk2